Making a Difference – Quality by Design (QbD)

With pharma often reluctant to make use of innovation when it comes to manufacturing, it is necessary to implement regulatory policies to encourage industry-wide adoption of novel technology. Using a Quality by Design approach can provide an answer, resulting in lower costs and shorter project timelines.

The drive to move drugs from development to market as efficiently and effectively as possible is omnipresent. However, the pharmaceutical industry has often been reluctant to new, innovative and potentially beneficial systems over the years that could reduce time to market. Much of this has been due to uncertainty over how regulators would respond to such innovations, and how this might actually make development and registration processes more lengthy and/or costly, rather than improving them.

Download the article “Making a Difference” published in European Pharmaceutical Contractor, March 2015